NasdaqGS:AMLXPharmaceuticals
The Bull Case For Amylyx Pharmaceuticals (AMLX) Could Change Following LUCIDITY Trial Enrollment Milestone Completion
Amylyx Pharmaceuticals recently reported that it has fully enrolled and dosed all 78 participants in LUCIDITY, its pivotal Phase 3 trial of avexitide for post-bariatric hypoglycemia after Roux-en-Y gastric bypass surgery, with topline results expected in the third quarter of 2026.
This milestone locks in a clear timeline toward potential FDA review of a first-in-class GLP-1 receptor antagonist in a condition with no approved therapies.
We’ll now explore how completing LUCIDITY enrollment,...